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Abstract:  Glutamate excitotoxicity contributes to a variety of disorders in the central nervous system, which is triggered 
primarily by excessive Ca
2+ influx arising from overstimulation of glutamate receptors, followed by disintegration of the 
endoplasmic reticulum (ER) membrane and ER stress, the generation and detoxification of reactive oxygen species as well 
as mitochondrial dysfunction, leading to neuronal apoptosis and necrosis. Kainic acid (KA), a potent agonist to the  -amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate class of glutamate receptors, is 30-fold more potent in neuro-
toxicity than glutamate. In rodents, KA injection resulted in recurrent seizures, behavioral changes and subsequent degeneration
of selective populations of neurons in the brain, which has been widely used as a model to study the mechanisms of neurode-
generative pathways induced by excitatory neurotransmitter. Microglial activation and astrocytes proliferation are   
the other characteristics of KA-induced neurodegeneration. The cytokines and other inflammatory molecules secreted by 
activated glia cells can modify the outcome of disease progression. Thus, anti-oxidant and anti-inflammatory treatment 
could attenuate or prevent KA-induced neurodegeneration. In this review, we summarized updated experimental data with 
regard to the KA-induced neurotoxicity in the brain and emphasized glial responses and glia-oriented cytokines, tumor  
necrosis factor- , interleukin (IL)-1, IL-12 and IL-18.  
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INTRODUCTION 
  Excitotoxicity mediated by glutamate receptors may un-
derlay the pathology of a number of neurological abnormali-
ties, including Huntington’s chorea, Alzheimer’s disease 
(AD), and Parkinson’s disease (PD). Excitotoxic cell death is 
commonly induced experimentally by the administration of 
kainic acid (KA), a potent agonist to the  -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate class of 
glutamate receptors [1-3]. In rodents, injections of KA resulted 
in recurrent seizures, behavioral changes and subsequent de-
generation of selective populations of neurons in the brain [4, 
5]. Thus, administration of KA in rodents has been widely used 
as a model to study the mechanisms of neurodegenerative 
pathways induced by excitatory neurotransmitters. 
1. OVERVIEW OF EXCITOTOXICITY INDUCED BY 
GLUTAMATE  
  L-glutamate, the major excitatory transmitter in the brain 
and spinal cord, is associated with learning, cognition, mem-
ory and neuro-endocrine functions [6, 7]. The glutamate re-
ceptors can be divided into two broad categories: the 
ionotropic receptors that mediate fast postsynaptic potentials 
by activating ion channels directly, and the metabotropic 
receptors that results in the expression of slow postsynaptic 
potentials through second messengers [8, 9]. The action of 
glutamate on the ionotropic receptors is always excitatory 
[10, 11]. There are three major subtypes of ionotropic   
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glutamate receptors: AMPA, kainate, and N-methyl-D-
aspartate (NMDA), named according to the types of syn-
thetic agonists that activate them, respectively [12, 13]. The 
NMDA glutamate receptor is blocked by specific antagonists 
such as D(-)-2-amino-5-phosphonovalerate (APV) [14, 15]. 
Both AMPA and kainate receptors are blocked by 6-cyano-
7-nitroquinoxalin-2,3-dione (CNQX) [16, 17]. Thus the 
AMPA and kainate receptors are sometimes referred to to-
gether as non-NMDA receptors. The ion channel of NMDA 
receptor is a tetrameric structure that results from up to seven 
genes coding for seven subunits termed GluN1, GluN2A, 
GluN2B, GluN2C, GluN2D, GluN3A and GluN3B [18, 19]. 
The AMPA receptor family is composed of four subunits, 
GluA1–4 [20, 21]. The kainate receptor family comprises 
five genes, divided into two subfamilies, including GluK4-5 
and GluK1–3. GluK4 and GluK5 exhibit higher affinity for 
kainate than GluK1–3 [22, 23]. Herein, we used the new 
nomenclature for glutamate receptors recommended by the 
International Union of Pharmacology Committee on Recep-
tor Nomenclature and Drug Classification (NC-IUPHAR) 
[24]. NC-IUPHAR recommended and previous nomencla-
tures of ionotropic gluatamate receptor subunits are listed in 
Table 1.
  Excessive amounts of glutamate are highly toxic to neu-
rons, an action termed glutamate excitotoxicity [25, 26]. Glu-
tamate excitotoxicity is triggered primarily by excessive Ca
2+
influx arising from overstimulation of the NMDA subtype of 
glutamate receptors, followed by disintegration of the endo-
plasmic reticulum (ER) membrane and ER stress, the genera-
tion of reactive oxygen species (ROS) as well as mitochon-
drial dysfunction, leading to neuronal apoptosis and necrosis 
[27, 28]. There is increasing realization that the mitochon-KA-Induced Excitotoxicity  Current Neuropharmacology, 2011, Vol. 9, No. 2    389
drial dysfunction occupies the center stage in these processes 
[28, 29]. In many cell types, glutamate neurotoxicity is   
induced by NMDA as well as non-NMDA receptors [25, 26, 
30]. 
2. KA ADMINISTRATION TO RODENTS INDUCES 
SEIZURES, SELECTIVE NEURODEGENERATION 
AND BEHAVIORAL CHANGES 
  Kainic acid (KA) is a non-degradable analog of   
glutamate and 30-fold more potent in neurotoxicity than   
glutamate [31-33]. Administration of KA to rodents caused  
a well characterized seizure syndrome, as described by   
Ben-Ari and other research groups [34, 35]. The seizure   
activity caused by intravenous, intraperitoneal, intranasal   
injections or microinjection into amygdala or hippocampus is  
divided in several distinct phases. During the first 20-30 min,  
the animals have “staring” spells, followed by head nodding  
and numerous wet-dog shakes for another 30 min. One hour  
after KA administration, the animal starts recurrent limbic  
motor seizures, including masticatory and facial movements,  
forepaws tremor, rearing and loss of postural control. The  
seizures then become progressively severer, with a reduction  
in the intermission. In the following l-2 h, the animal   
displays a full status epilepticus [34-36]. 
  KA-induced damage seriously impact the hippocampus. 
The hippocampus is particularly vulnerable to KA-induced 
neurotoxicity due to the high density of kainate receptors 
[37]. The hilar neurons are sensitive to KA-induced neuro-
toxicity, but neuron loss in the other areas of the hippocam-
pus differs between animal species and strains [38-40]. In 
rats, the systemic injections of KA produced widespread 
neuronal death, primarily in the hippocampus hilus, CA1 and 
CA3 areas [30, 41]. Mouse strains vary significantly in their 
sensitivity to KA-induced neurodegeneration [39, 40, 42, 
43]. In general, the C57BL/6, C57BL/10, and (C57BL/6 x 
CBA/J) F1 strains are resistant to KA-induced neurodegen-
eration, while the FVB/N, ICR and DBA/2 J strains are vul-
nerable [40]. C57BL/6, the “relatively” resistant mouse 
strain, reveals significant neuronal damage in CA1 and CA3, 
and to a lesser extent, in the polymorphic layer of the dentate 
gyrus 12 h post-treatment of KA systemically detected by 
cupric-silver and Fluoro-Jade B staining [44, 45]. CA3 re-
gion has the highest abundance of kainate receptors, the acti-
vation of which can elevate the concentration of ROS and 
impair the normal function of mitochondria [46-48]. CA3 
neurons are directly excited by stimulation of their KA re-
ceptors and indirectly, by increased glutamate efflux secon-
dary to KA stimulation of mossy fibers [49, 50]. CA3 syn-
chronization produces spreading epileptiform activity that 
extends to CA1 and other limbic structures [51, 52] (Fig. 1).  
  CA1 pyramidal neurons receive two distinct excitatory 
inputs that are capable of influencing hippocampal output 
and involving in spatial memory and memory consolidation 
[53, 54]. Damage in CA1/CA3 regions of hippocampus in-
duced by KA mainly results in the spatial learning deficits 
[55, 56]. KA-treated Wistar rats are impaired in the water 
maze and object exploration tasks, and hyperactive in the 
open field test, which can be improved by physical exercise 
and the selective cyclooxygenase (COX)-2 inhibitor [57, 58]. 
Intraperitoneal injections of KA into the developing rat 
Table 1.  NC-IUPHAR Recommended and Previous Nomenclatures of Ionotropic Glutamate Receptor Subunits 
Ionotropic Glutamate 
Family 
NC-IUPHAR Subunit 
Nomenclature 
Previous Nomenclatures  Human Gene 
Name 
Human Chromosomal 
Location 
GluN1 GLUN1, NMDA-R1, NR1, GluR 1  GRIN1  9q34.3 
GluN2A GLUN2A, NMDA-R2A, NR2A, GluR1 GRIN2A  16p13.2 
GluN2B GLUN2B, NMDA-R2B, NR2B, hNR3, GluR2 GRIN2B  12p12 
GluN2C GLUN2C, NMDA-R2C, NR2C, GluR3 GRIN2C  17q25 
GluN2D GLUN2D, NMDA-R2D, NR2D, GluR4 GRIN2D  19q13.1 
GluN3A GLUN3A, NMDA-R3A, NMDAR-L, chi-1  GRIN3A  9q31.1 
NMDA 
GluN3B GLUN3B, NMDA-R3B,  GRIN3B  19p13.3 
GluA1 GLUA1, GluR1, GluRA, GluR-A, GluR-K1, HBGR1  GRIA1  5q31.1 
GluA2 GLUA2, GluR2, GluRB, GluR-B, GluR-K2, HBGR2  GRIA2  4q32-q33 
GluA3 GLUA3, GluR3, GluRC, GluR-C, GluR-K3  GRIA3  Xq25-q26 
AMPA 
GluA4 GLUA4, GluR4, GluRD, GluR-D  GRIA4  11q22 
GluK1 GLUK5, GluR5, GluR-5, EAA3  GRIK1  21q22.11 
GluK2 GLUK6, GluR6, GluR-6, EAA4  GRIK2  6q16.3-q21 
GluK3 GLUK7, GluR7, GluR-7, EAA5  GRIK3  1p34-p33 
GluK4 GLUK1, KA1, KA-1, EAA1  GRIK4  11q22.3 
Kainate 
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brains induce the impaired short-term spatial memory in   
the radial-arm maze, deficient long-term spatial learning   
and retrieval in the water maze, and a greater degree of   
anxiety in the elevated plus maze [59, 60]. Mice with a   
single unilateral injection of KA into the dorsal hippocampus 
exhibit a decrease in depression-like behavior in the forced 
swimming test and retarded acquisition as well as impaired 
retention of visual-spatial information in the Morris water 
maze test [61]. 
3. KA MEDIATES GENERATION OF OXIDATIVE 
STRESS 
  KA receptors have both presynaptic modulatory and di-
rect postsynaptic excitatory actions [62, 63]. The activation 
of KA receptors produces membrane depolarization and re-
sults in alteration in intracellular calcium concentrations, 
which is required to trigger the neuronal death cascade (Fig. 2)
[64]. KA can also induce the release of lactate dehydro-
genase (LDH), and a decrease in 3-(4, 5-dimethylthiazole-2-
yl)-2, 5-diphenyl tetrazolium bromide (MTT), which result 
in damage of mitochondrial function [2]. KA administra-
tion increases the generation of ROS and reactive nitrogen 
species (RNS). There is growing evidence that free radical 
generation plays a key role in the neuronal damage [65]. KA 
has been shown to immediately induce COX-2 expression 
that might be involved in hippocampal neuronal death [66]. 
Early induced COX-2 facilitates the recurrence of hippo-
campal seizures, and late synthesized COX-2 stimulates hip-
pocampal neuron loss after KA administration [67]. COX 
catalyzes the first step in the synthesis of prostanoids, includ-
ing prostaglandins (PGs), prostacyclin, and thromboxanes. 
PGE(2) is pathologically increased in the brain after KA 
treatment, and has been proven to be closely associated with 
neuronal death [68]. In addition, lipid peroxides play critical 
Fig. (1). The Input and Output Pathways of Hippocampal Formation. Entorhinal cortex (EC) is the main input to the hippocampus. EC 
projects to the dentate gyrus (DG) via perforant fiber pathway and provides the critical input to CA3 via mossy fiber pathway, then to CA1 
by means of the Schaffer collateral pathway. Additionally, EC can also project directly to CA3, CA1 and subiculum (Sub). Meantime, EC is 
the major output of the hippocampus. Arrows denote the direction of impulse flow. 
Fig. (2). Schematic Overview of KA-Mediated Neuronal Death. (1) By stimulating glutamate receptors (GluR), kainic acid (KA) elicits 
the increase of intracellular Ca
2+, activation of Ca
2+-dependent enzyme and production of free radicals; (2) Excessive Ca
2+ and free radicals 
cause mitochondrial dysfunction, release of mitochondrial factors, activation of caspase-3, leading to neuronal apoptosis; (3) KA causes the 
disintegration of the endoplasmic reticulum (ER) and ER stress with the activation of the ER proteins Bip, Chop, and caspase-12, involved in 
neuronal apoptosis; (4) Ca
2+ overload and excessive free radicals cause directly mitochondrial swelling, leading to neuronal necrosis. COX: 
cyclooxygenase; ROS: reactive oxygen species; RNS: reactive nitrogen species. 
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roles in the initiation and modulation of inflammation and 
oxidative stress upon KA insult. Seizures can induce the 
products of lipid peroxidation, such as F(2)-isoprostanes and 
Isofurans, which have been thought to be the reliable indices 
of oxidative stress in vivo [69]. Moreover, KA causes the 
disintegration of the ER membrane in hippocampal neurons 
and ER stress with the activation of the ER proteins Bip, 
Chop, and caspase-12 [70]. ER stress appears to act at an early 
stage of the cell death process prior to disruption of calcium 
homeostasis, excessive accumulation of ROS, and mitochon-
drial dysfunction [71]. Old astrocyte specifically induced sub-
stance (OASIS) is involved in the endoplasmic reticulum 
stress response [72]. A recent study showed that OASIS ex-
pressed in astrocytes plays an important role in protection 
against neuronal damage induced by KA [1]. 
4. GLIAL CELLS ARE ACTIVATED UPON KA   
ADMINISTRATION  
  KA-induced neuronal death is accompanied by increased 
activation of microglia and astrocytes [73-75]. Additionally, 
the activated glial cells cluster at the hippocampal lesions 
and the immunostaining reactivity is particularly strong 
around areas of debris (Fig. 3).  
Fig. (3). Glial cells activation accompanied the neuronal death 7 
days after KA (45 mg/kg body weight) treatment to C57BL/6 
mice. (A) Obvious neuronal loss was showed in CA3 area of hip-
pocampus by Nissl’s staining. (B) CD11b positive cells (microglia) 
accumulated in the lesioned CA3 area. (C) GFAP positive cells 
(astrocytes) spread the whole hippocampus, especially in CA3 area. 
Arrows in A indicate the areas of neuronal loss. 
4.1. Microglia 
  Microglia account for approximately 20% of the total 
glial population in the central nervous system (CNS). Micro-
glia are the main effector cell type of the immune and in-
flammatory responses in the CNS, as earlier reviewed by 
Streit and his colleagues [76]. The normal role of microglia 
could be partly connected to neuroprotection, whereas in 
pathological conditions microglia may become disease-
promoting cells. Upon neuronal injury, microglia rapidly 
acquire changes in morphology and secrete a variety of solu-
ble mediators [77, 78] (Fig. 4). Some studies suggested that 
the activated microglia might exert a neuroprotective func-
tion, especially in multiple sclerosis (MS) and its animal 
model, experimental autoimmune encephalomyelitis (EAE) 
by creating a microenvironment for reparative and regenera-
tive processes [79]. Evidence is also accumulating that acti-
vated microglia induce and/or exacerbate neuropathological 
changes in several CNS diseases such as AD and PD through 
secreting proinflammatory and neurotoxic factors [80, 81]. In 
KA-induced hippocampal injury, microglial activation is 
generally believed to contribute to neuroinflammation and 
neurodegeneration [74, 82, 83]. A recent study showed that 
IB kinase/nuclear factor kappa B (NF-B) dependent mi-
croglial activation participated in KA-mediated injury in vivo
through induction of inflammatory mediators [82]. However, 
whether microglial activation initiates the disease progres-
sion or merely responds to neuronal death is still unclear.  
4.2. Astrocytes 
  Astrocytes, the most numerous glia cells, have been re-
garded as passive supporters of neurons in CNS for decades. 
Studies of the last 20 years, however, challenged this as-
sumption by demonstrating that astrocytes possess functional 
neurotransmitter receptors [84, 85]. These findings have led 
to a new concept of neuron-glia intercommunication where 
astrocytes play an undoubted dynamic role by integrating 
neuronal inputs and modulating synaptic activity, and so 
contribute to disease development [86]. Astrocytes have 
functional receptors for the excitatory neurotransmitter glu-
tamate and respond to physiological concentrations of this 
substance with oscillations in intracellular Ca
2+ concentra-
tions and spatially propagating Ca
2+ signals [87-89]. In vitro
studies provided evidence that astrocytes can take up gluta-
mate at synapses and release glutamate in a calcium-
dependent manner [90]. A proliferative response of astro-
cytes at two days after KA treatment has been reported al-
ready in 1981 [91]. The expression of glial fibrillary acidic 
protein (GFAP) has been shown to steadily increase from 
one/three days up to one month after intra-hippocampal or 
intraperitoneal injection of KA [92, 93]. Astrogliosis induced 
by excitotoxicity has been considered as a marker for neuro-
toxicity [73, 94]. Activated astrocytes produce pro- and anti-
inflammatory cytokines, chemokines, neurotrophic factors 
and other modulators to be involved in neuron-glia commu-
nication (Fig. 5 ). It is believed that astrocytes produce 
growth factors to prevent neurons from death and to promote 
proliferation and differentiation of precursor cells [95-97]. 
Activation of transcription factors, including nuclear factor 
erythroid-2-related factor 2 (Nrf2) and NF-B, in astrocytes 
induces the neuroprotective molecule expression and confers 
protection to neighboring neurons [98-100]. 
5. ALTERED CYTOKINE EXPRESSION AFFECTS 
KA-INDUCED INJURY 
  Altered expression of cytokines in response to brain in-
jury has diverse actions that can exacerbate, mediate, reduce 
or inhibit neuronal damage and influence the disease devel-392 Current Neuropharmacology, 2011, Vol. 9, No. 2 Zhang and Zhu 
opment in a variety of CNS disorders, such as AD, MS, viral 
or bacterial infections, ischemia, stroke, and various forms of 
encephalopathies [101-105]. Cytokines can be divided into 
pro-inflammatory and anti-inflammatory cytokines, which 
play the neurodestructive and neuroprotective roles, respec-
tively. It is the balance between destructive and protective 
factors that ultimately determines the net result of the neuro-
immune and neuro-inflammation interaction, as reviewed by 
Kerschensteiner et al. [106]. Results from studies using KA 
model also indicated that cytokines are involved in neuron-
glia intercommunication and manipulation of pro- and anti-
inflammatory cytokines can modify the outcome with regard 
to the seizure activity, behavioral changes as well as the neu-
ropathological consequences [75, 107-109] (Fig. 6). The 
roles of several important cytokines in the CNS disorders are 
reviewed here, including tumor necrosis factor-  (TNF- ), 
interleukin-1 (IL-1), IL-12 and IL-18. 
5.1. TNF- 
  Tumor necrosis factor-  (TNF- ) is mainly produced by 
microglia and astrocytes in the CNS. Its functions are medi-
ated through two receptors, TNF receptor (TNFR) 1 (p55) 
and TNFR2 (p75), both of which are expressed on various 
cells types [110]. TNF-  over-expression participates in the 
pathogenesis of several CNS disorders, such as AD [111], 
bacterial meningitis [112], MS [113] and cerebral malaria 
[114]. TNF-  potentiates excitotoxic injury to human fetal 
brain cells [115]. In contrast to its well known deleterious 
roles, multiple lines of evidence suggested that TNF-  also 
exhibit neuroprotective properties. This implies an intricate 
biological function of TNF- in modulating immune and 
inflammatory responses. TNF-  knockout worsens Listeria 
infection in the CNS [116] and TNF-  receptor knockout 
enhances the neuronal damage after excitotoxic [108, 117], 
ischemic [118] or traumatic injury [119]. Our study showed 
that mice lacking TNFR1 exhibited a more severe seizure 
activity, hippocampal neurodegeneration and increased mi-
croglial activation, suggesting that TNF-  plays its protective 
role through TNFR1 signaling [108], which is in agreement 
with a previous report [120]. Another study also proved that 
the protective roles of TNF-  in KA-induced neurodegenera-
tion are via TNFR2 signaling [117]. Several neuroprotective 
Fig. (4). The Categories of Molecules Produced by Activated Microglia. IL: interleukin; TNF: tumor necrosis factor; TGF: transforming 
growth factor; IL-1ra: IL-1 receptor antagonist; MIP: macrophage inflammatory protein; MDC: macrophage-derived chemokine; MCP: 
monocyte-chemoattractant protein; RANTES: regulated on activation normal T cell expressed and secreted; IFN: interferon; IP: IFN-
inducible protein; R: receptor; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; NT: neurotrophin; MHC: major histo-
compatibility complex; CR: complement receptor; C1qRp: C1q receptor for phagocytosis enhancement; FasL: Fas ligand; PG: prostaglandin; 
COX: cyclooxygenase; NO: nitric oxide; ROS: reactive oxygen species; RNS: reactive nitrogen species; MMP: matrix metalloproteinase; 
NSAIDs: nonsteroidal antiinflammatory drugs.
Fig. (5). The Categories of Molecules Produced by Activated Astrocytes. ROS: reactive oxygen species; IL: interleukin; TNF: tumor 
necrosis factor; IFN: interferon; CSF: colony-stimulating factor; GM-CSF: granulocyte-macrophage CSF; TGF: transforming growth factor; 
MCP: monocyte-chemoattractant protein; RANTES: regulated on activation normal T cell expressed and secreted; IP: IFN-inducible protein; 
NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; bFGF: basic fibroblast growth factor; MMP: matrix metalloproteinase. 
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molecules were identified as TNFR1 targets, including 
members of the Bcl-2 family, DNA repair machinery and 
cell cycle, developmental, and differentiation factors, neuro-
transmitters and growth factors, as well as their receptors 
[121]. The mechanisms by which TNF reduced neuron loss 
after brain injury may involve the up-regulation of proteins, 
such as neuronal apoptosis inhibitor protein (NAIP), which 
maintain calcium homeostasis and reduce free radical gen-
eration [122].  
5.2. IL-1 
  IL-1 plays a pivotal role in the neuroinflammation that 
has been well addressed in KA induced neurodegenerative 
model [109, 123]. Systemic KA administration induced the 
expression of IL-1, IL-1 receptor antagonist and IL-1 con-
verting enzyme as early as 3 h, 12 h, and 24 h post-treatment, 
respectively, which is localized in the areas known to display 
neuronal and tissue damage upon excitotoxic lesions [124, 
125]. Recombinant IL-1 receptor antagonist has dose- and 
region-dependent effects on neuronal survival after KA 
treatment and prevents damage-induced changes in amyloid 
precursor protein and GFAP mRNAs [126]. It has also been 
shown that IL-1 is activated in the cerebellum with sys-
temic administration of KA, and its type I receptor (IL-1R) is 
expressed at a soma of cerebellar Purkinje cells [127]. The 
proconvulsive actions of IL-1 in the hippocampus may de-
pend on the activation of a sphingomyelinase- and Src-
family of kinases-dependent pathway which leads to the 
phosphorylation of the GluN2B subunit [128].  
5.3. IL-12 
  IL-12 is a heterodimeric cytokine that consists of a heavy 
chain, p40, and a light chain, p35 [129]. In the CNS, micro-
glia and astrocytes are the main source of producing IL-12 
[130]. Human CNS-derived microglia produce IL-12 in vitro
after activation with LPS and IFN- [131]. Murine microglia 
can be induced to express mRNA encoding the IL-12 recep-
tor (IL-12R) [132], indicating an autocrine regulation path-
way of IL-12 in these cells. IL-12 plays a critical role in sev-
eral CNS diseases, such as MS and Borna disease. IL-12p40 
is increased in cerebrospinal fluid and serum of MS patients 
[133]. Mice lacking IL-12p40 or administered with anti-IL-
12p40 monoclonal antibodies are resistant to the develop-
ment of EAE [134, 135]. In contrast, IL-12p35 deficient 
mice are susceptible to EAE [114]. Borna disease virus, 
which does not trigger disease in most strains, is harmful 
after infecting the CNS of mice that overexpress IL-12, sug-
gesting an important role of IL-12 in viral infection of the 
CNS [136]. IL-12 is an active participant in excitotoxic brain 
injury as suggested by our previous observation that IL-
12p35 deficiency alleviates KA-induced hippocampal neu-
rodegeneration [107] and by another finding that IL-12 ex-
pression is reduced in hippocampi of transgenic mice pro-
tected against KA-induced excitotoxicity by metallothionein 
overexpression [137].  
5.4. IL-18 
  Interleukin (IL)-18 is most closely related to IL-1. The 
similarities between both cytokines comprise structure, re-
ceptor complex, and pro-inflammatory properties [138]. IL-
18 serves as a link between innate and adaptive immune re-
sponses, such as stimulating the expression of adhesion 
molecules, inducing the production of chemokines (IL-8) 
and cytokines (TNF-  and IL-6), stimulating the activity of 
NK cells, and promoting T helper 1 (Th1) cells responses in 
combination with IL-12, Th2 responses in combination with 
IL-4, and Th17 responses in combination with IL-23 [139]. 
IL-18 and IL-18 receptor (IL-18R) mRNA have been found
in brain tissue and in cultured astrocytes and microglia [140]. 
IL-18 enhanced postsynaptic AMPA receptor responses in 
CA1 pyramidal neurons via the release of glutamate, thereby 
facilitating basal hippocampal synaptic transmission [141].
IL-18 deficient mice showed a diminished microglial activa-
tion and reduced dopaminergic neuron loss after acute 1-
methy-4-phenyl-1,2,3,6-tetrahydropyridine treatment [142]. 
The roles of IL-18 in KA-induced model are controversial. 
Fig. (6). Cytokines Involved in Neuron-glia Intercommunication. KA administration enhances further release of endogenous excitatory 
amino acids, activates microglia and astrocytes. Activated glial cells secrete inflammatory molecules, e.g. cytokines, chemokines, and neu-
rotrophins to influence the outcome of neuronal damage. Glu/KA: glutamate/kainic acid; GluR: glutamate receptors; TGF: transforming 
growth factor; IL: interleukin; TNF: tumor necrosis factor. 
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Levels of IL-18 and IL-18R in hippocampus increase pro-
gressively from day 1 and peaked at day 3 post-KA treat-
ment [143]. Interestingly, intracerebellar coinjection of IL-18 
counteracts the effect of IL-1 in KA-induced ataxia in mice 
[144]. We showed that exogenous IL-18 administration ag-
gravated the KA-induced injury in normal C57BL/6 mice, 
while in the condition of IL-18 deficiency, IL-12 could over-
compensate the function of IL-18 and worsen the seizure 
activity as well as hippocampal neurodegeneration [75].  
6. THERAPEUTIC STRATEGIES 
  Considering that oxidative stress is central to KA-
induced excitotoxic damage, anti-oxidant and anti-
inflammatory treatments may attenuate or prevent the KA-
mediated neurodegeneration (Fig. 7). The potential role of 
COX-2 inhibitors as a new therapeutic drug for the neuron 
loss after KA treatment has been studied. The selective 
COX-2 inhibitors, celecoxib, NS398, rofecoxib and 
SC58125, can suppress an elevation of PGE (2) and block 
hippocampal cell death [57, 145]. The other drugs tested 
experimentally include curcumin, fluoxetine, ethyl pyruvate 
and statins, whose neuroprotective effects are associated 
with their anti-inflammatory and anti-oxidant effects [146]. 
Free radical scavengers are well known to prevent neuron 
loss induced by exposure to excitotoxins. Edaravone (Ed), a 
newly developed free radical scavenger, could inhibit lipid 
peroxidation and prevent neuron loss when administered 
after the onset of seizures in a KA-induced neurodegenera-
tive animal model [147]. The pineal secretory product, mela-
tonin, has free-radical-scavenger and antioxidant properties, 
which attenuates KA-induced neuronal death, lipid peroxida-
tion, and microglial activation [148]. Several phospholipase 
A (2) inhibitors, quinacrine and chloroquine, arachidonyl 
trifluoromethyl ketone, bromoenol lactone, cytidine 5-
diphosphoamines, and vitamin E, have been shown to pre-
vent the neurodegeneration in KA-mediated neurotoxicity 
[149]. Moreover, inhibition of ER stress by small molecular 
compounds, such as salubrinal, may benefit for treatment of 
KA-mediated neurotoxicity [70]. Furthermore, the microtu-
bule interacting drug candidate NAP has been shown to pro-
tect against KA toxicity via regulating the expression of key 
genes involved in the epileptogenic pathway [150]. A novel 
approach to engineer patient derived adult stem cells for 
therapeutic adenosine delivery in autologous cell transplanta-
tion has been proved to suppress seizure activity and protect 
hippocampal neurons from KA-induced damage [151]. Addi-
tionally, targeting the pro-inflammatory cytokines, by block-
ing the unique signal transduction of the specific cytokine is 
another potential therapeutic strategy.  
7. CONCLUDING REMARKS 
  Glutamate excitotoxicity contributes to a variety of CNS 
diseases, which is involved in overstimulation of glutamate 
receptors, excessive Ca
2+ influx, ER stress, generation of 
ROS and mitochondrial dysfunction, leading to neuronal 
damage. KA is a potent agonist to the AMPA/kainate class of 
glutamate receptors, which can result in seizures, behavioral 
changes and neurodegenration in susceptible brain regions 
like the hippocampus in rodents. 
  The activated glia cells and subsequent secretion of in-
flammatory molecules can modify the outcome of disease 
progression. By inhibiting one of the major components of 
the neuroinflammatory response after KA treatment, there 
could be less inflammation and neuronal loss, therefore an 
improvement of cognitive function.  
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